Vaccine Effectiveness against DS-1–Like Rotavirus Strains in Infants with Acute Gastroenteritis, Malawi, 2013–2015

Atypical DS-1–like G1P[8] rotaviruses emerged in 2013 in Malawi after rotavirus vaccine introduction. Vaccine effectiveness among infants hospitalized with acute DS-1–like G1P[8] rotavirus gastroenteritis was 85.6% (95% CI 34.4%–96.8%). These findings suggest that vaccine provides protection against these strains despite their emergence coinciding with vaccine introduction.

Previously, we demonstrated that all G1P [8] strains detected before Rotarix introduction in Malawi had a Wa-like genetic backbone (10). Shortly after Rotarix introduction, atypical DS-1-like G1P [8] rotavirus strains were detected, which provided an opportunity to examine whether emergence of DS-1-like G1P [8] strains could be the result of reduced protection afforded by the Wa-like G1P [8] Rotarix vaccine.

The Study
We used enzyme immunoassay (EIA) to detect rotaviruses in stool samples collected from children <5 years of age with acute gastroenteritis at Queen Elisabeth Central Hospital (QECH; Blantyre, Malawi) (2). We used reverse transcription PCR to assign G and P genotypes to rotaviruspositive samples (10,11). Samples with sufficient volume and containing G1 (n = 110), G2 (n = 64), or other (G4, G9, or G12, n = 42) rotavirus strains were selected at random during January 2013-December 2015.
We calculated rotavirus VE using logistic regression to compare 2-dose versus 0-dose vaccination status among hospitalized strain-specific rotavirus diarrhea case-patients and concurrently hospitalized control patients with non-rotavirus-caused diarrhea, matched by age at admission. We defined concurrency of controls for each endpoint (Table) as any patient hospitalized for diarrhea who tested negative for rotavirus occurring in the same date range (between the first and last hospitalized strain-specific case) in which cases of strain-specific rotavirus were detected. We limited VE analysis to infants <12 months of age because previous analysis did not demonstrate statistically significant protection in the second year of life (VE 31.7%, 95% CI -140.6% to 80.6%) (2). We obtained ethics approval from the National Health Sciences Research Committee, Malawi (867), and the Research Ethics Committee of the University of Liverpool, Liverpool, UK (000490).

Conclusions
Atypical DS-1-like G1 rotavirus strains emerged in Malawi shortly after Rotarix vaccine introduction (10). Although strain oscillation and emergence of novel types have been reported globally in the absence of vaccination, the mechanisms driving this phenomenon are not well understood. It is possible that the emergence of these DS-1-like G1P [8] strains was coincidental with vaccine introduction. The high VE strongly suggests that escape from vaccine-induced immunity is not the driver for emergence. The swift decline in prevalence of these strains is in contrast with more sustained changes in strain circulation described in other settings in the context of high VE (13). The decline could have been precipitated by the observed high VE or may represent a natural phenomenon related to viral fitness and associated periodic nature of the circulation of the DS-1-like strains, which has been observed historically and globally in the absence of vaccine. These findings support continued use of rotavirus vaccine in this population as an intervention to reduce severe diarrhea caused by rotavirus strains possessing either Wa-like or DS-1-like genetic backbones. The observed decline in rotavirus hospitalizations in children after vaccine introduction (2), together with reduction in infant diarrhea deaths in Malawi (14), are public health benefits that could be sustained through rotavirus vaccination in this region, which has one of the highest burdens of rotavirus disease.
The VE against DS-1-like G1P [8] strains in this study resembles our previous findings of VE of 82% (95% CI 42%-95%) against all G1P [8] strains 3 years after vaccine introduction (2013-2015) (2). In contrast, we were unable to demonstrate statistically significant VE against DS-1like G2 rotaviruses despite a comparable number of such strains, consistent with our earlier study (VE 45.9%, 95% CI −47.0% to 80.1%; p = 0.228) (2). The apparently lower VE against rotavirus disease caused by DS-1-like strains associated with G2, but not with G1P [8], lends support to the proposed dominant role of the outer capsid proteins VP7 and VP4 as drivers of homotypic protection. Although increasing evidence suggests that Rotarix vaccine does not provide the same degree of protection against G2 strains as G1 strains, this difference in protection appears to have little effect on total VE among populations in which vaccination performs optimally and high VE is maintained. However, the difference in protection between the strains may exacerbate underperformance of rotavirus vaccines in low-resource settings such as Malawi, where overall VE is generally lower for reasons that remain poorly understood (2,15). We could not demonstrate statistically significant effectiveness against Wa-like G1P [8] rotaviruses (p = 0.23). Wa-like G1P [8] cases became dominant and replaced DS-1-like G1P [8] once vaccine coverage had reached high and stable levels ( Figure). At high population vaccine coverage, case-control analysis of VE became challenging and difficult to power sufficiently.
Our data demonstrate that Rotarix provides a high degree of protection against severe disease caused by homotypic G1P [8] rotaviruses in Malawi regardless of genomic backbone. VE for patients <1 year of age is comparable to that seen in middle-income countries. The lower VE against heterotypic G2P [4] strains previously described (15) suggests that more detailed immune response studies, clarification of the correlates of protection for rotavirus disease, and strain surveillance are needed to monitor the impact of sustained, high vaccine coverage on rotavirus strain distribution. Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 9, September 2019